Angiotensin II receptor blockers for the treatment of hypertension

Bibliography

• KANNEL WB, WILSON PW: Cardiovascular risk factors and hypertension. In: Hypertension Primer: The Essentials of High Blood Pressure. 2' ed. Izzo JL and Black HR (Eds.) Lippincott Williams & Wilkins, Dallas, Texas, USA: (1999):199–202.
   Google Scholar
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-). Arch. Intern. Med. (1997) 157:2413–2446.
   PubMed Web of Science ®Google Scholar
• Deaths: Final Data for 1998. Natl. Vital Stat. Rep. (2000) 48(11):5.
   Google Scholar
• MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men. N Engl. j Med. (1993) 328:914–921.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR, LARAGH JH, BAER L et al: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl. J. Med. (1972) 286(9):441–449.
   PubMed Web of Science ®Google Scholar
• SEALY JE, BLUMENFELD JD, BELL GM et al.: On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. _J.. (1988) 6(10):763–777.
   Google Scholar
• SKID GEL RA, ERDOS EG: Angiotensin I-converting enzyme. In: Hypertension Primer: The Essentials of High Blood Pressure. 2'd Ed. Izzo JL and Black HR (Eds.), Lippincott Williams & Wilkins, Dallas, Texas, USA (1999):19.
   Google Scholar
• RACO D: ACE inhibitors. Clin Rev Whiter. (1998):7–11.
   Google Scholar
• GOODFRIEND T: Angiotensins: actions and receptors. In: Hypertension Primer: The Essentials of High Blood Pressure. 2'd Ed. Izzo JL and Black HR (Eds.), Lippincott Williams & Wilkins, Dallas, Texas, USA (1999):11.
   Google Scholar
• SEE S, STIRLING A: Candesartan cilexetil. Am. j Health Syst. Pharm. (2000) 57(8):739–746.
   PubMed Web of Science ®Google Scholar
• KAPLAN NM: Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? j Hum. Hypertens. (2000) 14\(Suppl. 1):S87–S90.
   Google Scholar
• GOODFRIEND TL, ELLIOTT ME, CATT JK: Drug Therapy: angiotensin receptors and their antagonists. N Engl Med. (1996) 334(25):1649–1654.
   PubMed Web of Science ®Google Scholar
• WEBER M: Angiotensin II receptor blockers. In: Hypertension Primer: The Essentials of High Blood Pressure. 2m ed. Izzo JL and Black HR (Eds.), Lippincott Williams & Wilkins, Dallas, Texas, USA (1999):377–378.
   Google Scholar
• ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med. (1992) 117:234–242.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of ACEI-associated cough and angioedema. Includes proposed mechanisms.
   Google Scholar
• PLOSKER GL, FOSTER RH: Eprosartan: a review of its use in the management of hypertension. Drugs (2000) 60(1):177–201.
   PubMed Web of Science ®Google Scholar
• ISRAILI ZH: Clinical pharmacokinetics of angiotensin II (AT 1) receptor blockers in hypertension. I Hum. Hypertens. (2000) 14\(Suppl. 1):S73–S86.
   Google Scholar
• Atacand package insert. Wayne, PA: Astra Pharmaceuticals (1998).
   Google Scholar
• Avapro package insert. Princeton, NJ: Bristol-Myers Squibb Company (1998).
   Google Scholar
• Diovan package insert. East Hanover, NJ: Novartis Pharmaceuticals (1998).
   Google Scholar
• Micardis package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals.
   Google Scholar
• Cozaar package insert. West Point, PA: Merck & Co (1999).
   Google Scholar
• Teveten package insert. Buffalo Grove, IL: Unimed Pharmaceuticals (1999).
   Google Scholar
• OPARIL S: Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. I Hypertens. (2000) 13:18S–24S.
   Google Scholar
• NISHIKAWA K, NAKA T, CHATANI YOSHIMURA Y: Candesartan cilexetil: a review of its preclinical pharmacology. Hum. Hypertens. (1999) 11\(Suppl. 2):59–S17.
   Google Scholar
• Drugs for hypertension. Med. Lett. Drugs Ther. (2001) 43(1099):17–22.
   Google Scholar
• SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide induced. Kidney Int. (1999) 56(5):1879–1885.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, ARCURI KE, GOLDBERG Al etal.: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (1995) 25:1345–1350.
   Google Scholar
• •Study showing that losartan doses greater than 50mg showed no improvement.
   Google Scholar
• OPARIL S, DYKE S, HARRIS F et al: The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Chh. Ther (1996) 18(5):797–810.
   Google Scholar
• HEDNER T, HIMMELMANN A: The efficacy and tolerance of one and 2 daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. I Hypertens. (1999) 17(1):129–136.
   Web of Science ®Google Scholar
• GUTHRIE R, SAINT R, HERMAN T, PLESKOW W, SPRECHER D, COLLINS G: Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist in primary hypertension. Clin Dug Invest. (1998) 15(3):217–227.
   Web of Science ®Google Scholar
• NEUTEL JM, SMITH DHG: Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisatan in patients with mild to moderate hypertension. Adv. Ther. (1998) 15(4):206–217.
   Web of Science ®Google Scholar
• ELMFELDT D, GEORGE M, HUBNER R et al.: Candesartan cilexetil a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effect. I Hum. Hypertens. (1997) 11 (Suppl. 2):S49–53.
   Google Scholar
• •A meta-analysis of six, randomised, double-blind, placebo-controlled dose-response studies of candesartan.
   Google Scholar
• BAKRIS G, GRADMAN A, REIF M et al: efficacy of candesartan in comparison to losartan: The CLAIM study. Gum. Hypertens. (2001) 3(1):16–21.
   Google Scholar
• •This study showed that candesartan is superior to losartan at maximal doses.
   Google Scholar
• MALLION JM, LACOURCIERE Y, TELMISARTAN BLOOD PRESSURE MONITORING GROUP: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. I Hum. Hypertens. (1999) 13:657–664.
   PubMed Web of Science ®Google Scholar
• •This study showed that telmisartan is just as efficacious as losartan in mild-to-moderate hypertension.
   Google Scholar
• KASSLER-TAUB K, LITTLEJOHN T, EILLIOTT W, RUDDY T, ADLER E: Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am. J Hypertens. (1998) 11:445–453.
   PubMed Web of Science ®Google Scholar
• •This study showed that irbesartan is superior to losartan at maximal doses.
   Google Scholar
• MCCLENNAN KJ, MARKHAM A: Telmisartan. Drugs (1998) 56(6):1039–1044.
   PubMed Web of Science ®Google Scholar
• MESSERLI HF, WEBER MA, BRUNNER HR: Angiotensin II receptor inhibition: a new therapeutic principle. Arch. Intern. Med. (1996) 156(17):1957–1965.
   PubMedGoogle Scholar
• FUCHS SA, KOOPMANS HJ, BRODIE-MEIJER CE, MEYBOOM RHB: Are Angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension (2001) 37(1):el-e3.
   Google Scholar
• CHA YJ, PEARSON VE: Angioedema due to losartan. Ann. Pharmacother. (1999) 33(9):936–938.
   PubMed Web of Science ®Google Scholar
• ACKER CG, GREENBERG A: induced by the Angiotensin II blocker losartan. N Engl. I Med. (1995) 333(23):1572.
   PubMed Web of Science ®Google Scholar
• FRYE CB, PETTIGREW TJ: Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy (1998) 18(4):866–868.
   PubMed Web of Science ®Google Scholar
• RIVERA JO: Losartan-induced angioedema. Ann. Pharmacother. (1999) 33(9):933–935.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J Med. (2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• PARVING HH, LEHNERT H,-MORTENSEN, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl. I Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. I Med. (2001) 345: 861–9.
   Google Scholar
• Primary hypertension: Natural history, special populations and evaluation. In: Clinical Hypertension. 7th ed. Kaplan N (Ed.) Williams & Wilkins, Baltimore, MD, USA, (1998):111.
   Google Scholar
• JAMALI AFT, WILSON TANG WH, KHOT UN, FOWLER MB: The role of angiotensin II receptor blockers in the management of CHF. Arch. Intern. Med. (2001) 161:667–672.
   PubMedGoogle Scholar
• •A good review of the pathophysiology of CHE
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al: trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• •Losartan decreased all-cause mortality by 46% versus captopril in Class II - IV CHF patients.
   Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R etal.: Effect of losartan compared with captopril on mortality in patients with symtomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1586.
   Google Scholar
• •Losartan and captopril had similar effects on survival in Class II - IV CHF patients.
   Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D et.: Comparison of Candesartan, Enalapril, and their combination in congestive heart failure-Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation (1999) 100:1056–1064.
   Google Scholar
• •The first study to look at combination of ACEIs and ARBs for CHE
   Google Scholar
• COHN JN, TOGNONI G, GLAZER RD, D, HESTER A: Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor, on morbidity and mortality in chronic congestive heart failure. j Cardiac Fail. (1999) 5(2):155–160.
   PubMed Web of Science ®Google Scholar
• •This study showed that valsartan significantly decreased mortality and morbidity and CHF hospitalisations in Class II and III CHF patients versus placebo.
   Google Scholar
• DAHLOF B, DEVEREUX R, DE FAIRE U etal.: The losartan intervention for endpoint reduction (LIFE) in hypertension study, rationale, design, and methods. Am.. (1997) 10:705–713.
   Google Scholar